RESUMO
Mitral regurgitation (MR) is the most frequent valvular heart disease in developed countries. Surgical repair represents the optimal treatment for severe degenerative MR; however, surgical correction of functional MR is controversial. The Euro Heart Survey showed that up to 50 % of patients with severe MR are today denied surgical treatment. Therefore, new transcatheter techniques have been developed to treat MR with less invasive approaches. Currently, the device with the widest clinical use is the MitraClip System. In this scenario, a multidisciplinary team approach is key in providing optimal individually tailored treatment for patients with MR.
Assuntos
Cateterismo Cardíaco/estatística & dados numéricos , Anuloplastia da Valva Mitral/instrumentação , Anuloplastia da Valva Mitral/estatística & dados numéricos , Insuficiência da Valva Mitral/epidemiologia , Insuficiência da Valva Mitral/cirurgia , Radiografia Intervencionista/estatística & dados numéricos , Instrumentos Cirúrgicos/estatística & dados numéricos , Europa (Continente) , Medicina Baseada em Evidências , Humanos , Insuficiência da Valva Mitral/diagnóstico , Seleção de Pacientes , Prevalência , Desenho de Prótese , Resultado do TratamentoRESUMO
MitraClip system is the only catheter-based device for percutaneous mitral valve repair available for clinical use, after receipt of the CE Mark in 2008, while it is currently under review for FDA approval in the US. To date, over 3500 MitraClip implants have been performed worldwide, mainly in high risk surgical patients. The aim of this review is to review all the current evidences of the MitraClip therapy in an aim to define its clinical role in the treatment of mitral regurgitation (MR).